Liquid biopsy -
cfDNA and cfRNA sequencing
Minimally invasive tumor profiling from a standard blood sample by BostonGene, enabling the identification of biomarkers and monitoring of treatment response at both DNA and RNA levels.
.webp)
.webp)
.webp)
.webp)
Blood-based tumor genomic profiling with ctDNA assay
A comprehensive examination of the ctDNA fraction enables the identification of clinically relevant gene alterations, including SNVs, indels and gene rearrangements.
Treatment response and resistance monitoring
Comparison of pre-treatment and on-treatment ctDNA fraction levels to detect changes in molecular signatures.
Residual disease monitoring
Early detection of recurrence through the identification of ctDNA fraction in the blood following treatment.
General tumor profiling
Identification of actionable molecular events to guide treatment selection.
A panel of 216 genes includes:
A panel of 216 genes includes:
- 200 genes with complete exonic coverage
- 27 gene fusions
Tumor transcriptome insights with minimally invasive cfRNA assay
A transcriptome-driven exploratory engine applied to cfRNA analysis enables the investigation of tumor characteristics and transcriptional programs from a standard blood sample.
Gene expression levels assessment
Identification of drug targets and response biomarkers
Predictive gene expression signatures
PAM50 for breast cancer patients, prediction of metastasis localization and organ damage
Tumor microenvironment (TME) analysis
Characterization of TME composition and detection of tissue-resident immune cells
Identification of drug targets and response biomarkers
Predictive gene expression signatures
PAM50 for breast cancer patients, prediction of metastasis localization and organ damage
Tumor microenvironment (TME) analysis
Characterization of TME composition and detection of tissue-resident immune cells
.webp)
Explore BostonGene’s publications that demonstrate the utility of liquid biopsy
.webp)
Blood • November 28, 2023
A Novel Comprehensive Tumor-Informed Plasma cfDNA Assay to Monitor Minimal Residual Disease for Hematological and Solid Malignancies
Article
Blood • November 28, 2023
Molecular Findings on Plasma Cell-Free DNA Analysis Among Adults with Histiocytic Neoplasms
Article
.webp)
Cancer Research • April 1, 2023
Analytical validation of a liquid biopsy test using cell-free circulating tumor DNA for mutational profiling
Article
